Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Press Releases

Month Year

Month Year

Get News Alerts by Email

Jan 2, 2013

Trovagene to Study Transrenal BRAF Mutations in Primary and Metastatic Cancers

Study with MD Anderson will compare detection of BRAF mutations in urine to biopsy samples, and monitor therapeutic response, outcomes
Dec 26, 2012

Trovagene, Inc., Grants License for NPM1 Marker for Acute Myelogenous Leukemia to Leading Academic Medical Center
Dec 19, 2012

Trovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute Myelogenous Leukemia
Nov 27, 2012

Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
Nov 26, 2012

Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement

Show per page